Regeneron

Sanofi, Regeneron's Dupixent could hit $20B in peak sales with COPD expansion: analyst
Sanofi, Regeneron's Dupixent could hit $20B in peak sales with COPD expansion: analyst
Fierce Pharma
Sanofi
Regeneron
Dupixent
COPD
Flag link:
Sanofi and Regeneron's Dupixent scores trial win in tough-to-treat COPD
Sanofi and Regeneron's Dupixent scores trial win in tough-to-treat COPD
Fierce Pharma
Sanofi
Regeneron
Dupixent
COPD
clinical trials
Flag link:
FDA expands use of Regeneron's HoFH drug Evkeeza to kids 5 and up
FDA expands use of Regeneron's HoFH drug Evkeeza to kids 5 and up
Fierce Pharma
Regeneron
Evkeeza
pediatric
Homozygous Familial Hypercholesterolemia
FDA
Flag link:
AAD: Will Sanofi and Regeneron’s Dupixent be a game-changer or just another antibody on the COPD scrapheap?
AAD: Will Sanofi and Regeneron’s Dupixent be a game-changer or just another antibody on the COPD scrapheap?
Fierce Pharma
Sanofi
Regeneron
Dupixent
COPD
Flag link:
FDA Approves Regeneron-Sanofi's Sarilumab As First Biologic For Stiffness, Pain In Muscles
FDA Approves Regeneron-Sanofi's Sarilumab As First Biologic For Stiffness, Pain In Muscles
Yahoo/Benzinga
Regeneron
Sanofi
FDA
Kevzara
Sarilumab
polymyalgia rheumatica
Flag link:
Go or no go? Vaccines and neurology up for discussion
Go or no go? Vaccines and neurology up for discussion
EP Vantage
FDA
Acadia Pharmaceuticals
Apellis Pharmaceuticals
AstraZeneca
Biogen
Biomarin
Cidara Therapeutics
Emergent BioSolutions
GSK
Incyte
Ionis Pharmaceuticals
Melinta Therapeutics
Mundipharma
Novartis
Pfizer
Pharming
Regeneron
Roche
vaccines
RSV
ALS
COVID-19
Flag link:
Sanofi and Regeneron face a high-risk test for Dupixent
Sanofi and Regeneron face a high-risk test for Dupixent
EP Vantage
Sanofi
Regeneron
Dupixent
COPD
clinical trials
Flag link:
US government, Pfizer and others side with Sanofi and Regeneron in Supreme Court patent case
US government, Pfizer and others side with Sanofi and Regeneron in Supreme Court patent case
Endpoints
Pfizer
Viatris
Sanofi
Regeneron
patents
Supreme Court
Flag link:
In showdown with Roche, Regeneron gears up for potential Eylea expansion amid Covid decline
In showdown with Roche, Regeneron gears up for potential Eylea expansion amid Covid decline
Endpoints
Regeneron
earnings
Eylea
Flag link:
Top 10 Pharma TV Ad Spenders in 2022 — Anti-Inflammatories and Diabetes Drugs Dominate
Top 10 Pharma TV Ad Spenders in 2022 — Anti-Inflammatories and Diabetes Drugs Dominate
Xtalks
television ads
pharma marketing
DTC ads
AbbVie
Rinvoq
Dupixent
Sanofi
Regeneron
Skyrizi
Novo Nordisk
Ozempic
Jardiance
Eli Lilly
Boehringer Ingelheim
Rybelsus
Trulicity
Rexulti
Otsuka
Lundbeck
Tremfya
JNJ
Verzenio
Flag link:
In a win for Regeneron, Novartis' syringe for AMD drug declared 'unpatentable'
In a win for Regeneron, Novartis' syringe for AMD drug declared 'unpatentable'
Endpoints
Regeneron
Novartis
Eylea
drug delivery
patents
Lucentis
Flag link:
Coherus pays out $32M for exclusive US commercialization rights to Eylea biosimilar
Coherus pays out $32M for exclusive US commercialization rights to Eylea biosimilar
Endpoints
Coherus Biosciences
biosimilars
ophthalmology
Eylea
Regeneron
Flag link:
The Top New York Biopharma Companies Hiring Now
The Top New York Biopharma Companies Hiring Now
BioSpace
New York
hirings
Regeneron
Lundbeck
Schrödinger
Flag link:
Amgen files brief to Supreme Court ahead of oral arguments — with industry amicus support
Amgen files brief to Supreme Court ahead of oral arguments — with industry amicus support
Endpoints
Amgen
Sanofi
Regeneron
Supreme Court
legal
innovation
patents
Repatha
Praluent
Flag link:
10 clinical trials to watch in the first half of 2023
10 clinical trials to watch in the first half of 2023
BioPharma Dive
clinical trials
Alzheimer's disease
obesity
Huntington's disease
M&A
AstraZeneca
Daiichi Sankyo
Nimbus Therapeutics
Takeda
Eli Lilly
Sanofi
Regeneron
Moderna Therapeutics
Gilead Sciences
Pfizer
Roivant
Alnylam
uniQure
Flag link:
Biotech’s key upcoming clinical results
Biotech’s key upcoming clinical results
EP Vantage
clinical trials
Acadia Pharmaceuticals
Argenx
Arrowhead Pharmaceuticals
Biomarin
BioNTech
Daiichi Sankyo
Day One
EQRx
Fate Therapeutics
FibroGen
Gilead Sciences
Idorsia
Immunogen
Intellia Therapeutics
Karuna Therapeutics
Moderna Therapeutics
Regeneron
Roche
Travere Therapeutics
Vaxcyte
Flag link:
ASH: Roche touts Lunsumio's durable efficacy as AbbVie, Regeneron plot lymphoma bispecific battle
ASH: Roche touts Lunsumio's durable efficacy as AbbVie, Regeneron plot lymphoma bispecific battle
Fierce Pharma
Roche
ASH 2022
AbbVie
Regeneron
lymphoma
Lunsumio
glofitamab
Flag link:
Regeneron's Yancopoulos draws boos as he touts pharma innovation over cost considerations
Regeneron's Yancopoulos draws boos as he touts pharma innovation over cost considerations
Fierce Biotech
Regeneron
George Yancopoulos
innovation
Alzheimer's disease
Flag link:
Regeneron's Libtayo posts lung cancer win with Bristol's Yervoy. But company won't seek approval
Regeneron's Libtayo posts lung cancer win with Bristol's Yervoy. But company won't seek approval
Fierce Pharma
Regeneron
Libtayo
non-small cell lung cancer
Bristol Myers Squibb
Yervoy
Flag link:
UK regulators warn of ocular side effects after treatment with Sanofi's Dupixent
UK regulators warn of ocular side effects after treatment with Sanofi's Dupixent
Fierce Pharma
Regeneron
Sanofi
Dupixent
UK
side effects
Flag link:

Pages